Effects assessment: boron compounds in the aquatic environment.

Chemosphere

Environment Agency Austria, Spittelauer Lände 5, 1090 Vienna, Austria.

Published: January 2011

In previous studies, boron compounds were considered to be of comparatively low toxicity in the aquatic environment, with predicted no effect concentration (PNEC) values ranging around 1 mg B/L (expressed as boron equivalent). In the present study, we describe an evaluation of toxicity data for boron available for the aquatic environment by different methods. For substances with rich datasets, it is often possible to perform a species sensitivity distribution (SSD). The typical outcome of an SSD is the Hazardous Concentration 5% (HC5), the concentration at which 95% of all species are protected with a probability of 95%. The data set currently available on the toxic effects of boron compounds to aquatic organisms is comprehensive, but a careful evaluation of these data revealed that chronic data for aquatic insects and plants are missing. In the present study both the standard assessment factor approach as well as the SSD approach were applied. The standard approach led to a PNEC of 0.18 mg B/L (equivalent to 1.03 mg boric acid/L), while the SSD approach resulted in a PNEC of 0.34 mg B/L (equivalent to 1.94 mg boric acid/L). These evaluations indicate that boron compounds could be hazardous to aquatic organisms at concentrations close to the natural environmental background in some European regions. This suggests a possible high sensitivity of some ecosystems for anthropogenic input of boron compounds. Another concern is that the anthropogenic input of boron could lead to toxic effects in organisms adapted to low boron concentration.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chemosphere.2010.10.031DOI Listing

Publication Analysis

Top Keywords

boron compounds
20
aquatic environment
12
boron
9
compounds aquatic
8
toxic effects
8
aquatic organisms
8
ssd approach
8
b/l equivalent
8
boric acid/l
8
anthropogenic input
8

Similar Publications

Chemoresistance is an important factor in multiple myeloma (MM) relapse and overall survival. However, the mechanism underlying resistance remains unclear. In this study, we identified adenine nucleotide translocase 3 (ANT3) as a novel biomarker and therapeutic target for MM progression and resistance to the proteasome inhibitor bortezomib (BTZ).

View Article and Find Full Text PDF

[Clinical Analysis of 25 Cases of Acquired Hemophilia A in a Single Center].

Zhongguo Shi Yan Xue Ye Xue Za Zhi

December 2024

Department of Hematology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Hematology, Shijiazhuang 050000, Hebei Province, China.

Objective: To explore the diagnosis and treatment of acquired hemophilia A (AHA) based on the analysis of clinical data.

Methods: A retrospective analysis was conducted on the clinical manifestations, laboratory characteristics, treatment, and outcomes of 25 patients diagnosed with AHA who were admitted to the Second Hospital of Hebei Medical University.

Results: Among all patients, 11 cases had secondary factors, including 5 cases of autoimmune diseases, 3 cases of pregnancy-related disease, 1 case of pemphigoid, 1 case of Graves' disease, and 1 case of monoclonal gammaglobulinemia of unknown significance (MGUS).

View Article and Find Full Text PDF

[Clinical Characteristics and Risk Factors of Infection in Hospitalized Patients with Multiple Myeloma with New Generation Therapies].

Zhongguo Shi Yan Xue Ye Xue Za Zhi

December 2024

The Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital,Taiyuan 030000, Shanxi Province, China.

Objective: To evaluate the clinical characteristics and risk factors of infections occurring during hospitalization in patients with multiple myeloma(MM) treated with new generation therapies (including immuno- modulatory drugs, proteasome inhibitors and monoclonal antibodies).

Methods: The clinical data were collected from 155 patients with multiple myeloma who were treated in Shanxi Bethune Hospital from March, 2017 to March, 2022 and were retrospectively analyzed. For this study, the following therapies were considered to be new generation therapies: lenalidomide, pomadomide, bortezomib, ixazomib, daratumumab.

View Article and Find Full Text PDF

Utilization of renewable resources has become imperative, and considerable efforts have been devoted to tackling diverse global sustainability challenges, which contribute to the circular economy. The focus of this work was to optimize the extraction of polyphenolic compounds in bark using microwave-assisted (MAE) and ultrasonically assisted (UAE) extractions and evaluate the biological efficacies of the extracts. Additionally, the residue of the extracted pine bark was subjected to steam gasification to produce hydrogen-rich syngas and activated carbon.

View Article and Find Full Text PDF

Background/aim: Autologous stem cell transplantation (ASCT) is the standard strategy after induction therapy for newly diagnosed transplant-eligible multiple myeloma. High-dose melphalan (HDM) conditioning has been the recommended treatment regimen for a long time. No other conditioning regimen has been proven safer and more effective.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!